Inlyta is an oral medicine that is an angiogenesis inhibitor and VEGF/VEGFR inhibitor. It works by blocking proteins and signals to help slow down the growth of new blood vessels that fuel kidney tumor growth. Without new blood vessels, the cancer does not have a regular supply of oxygen and nutrients.